These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 11445735)

  • 1. Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis.
    Grinnell BW; Joyce D
    Crit Care Med; 2001 Jul; 29(7 Suppl):S53-60; discussion S60-1. PubMed ID: 11445735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New and emerging therapies for sepsis.
    Healy DP
    Ann Pharmacother; 2002 Apr; 36(4):648-54. PubMed ID: 11918516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated protein C versus protein C in severe sepsis.
    Yan SB; Dhainaut JF
    Crit Care Med; 2001 Jul; 29(7 Suppl):S69-74. PubMed ID: 11445737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis.
    Dhainaut JF; Yan SB; Cariou A; Mira JP
    Crit Care Med; 2002 May; 30(5 Suppl):S318-24. PubMed ID: 12004254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis.
    Dhainaut JF; Yan SB; Margolis BD; Lorente JA; Russell JA; Freebairn RC; Spapen HD; Riess H; Basson B; Johnson G; Kinasewitz GT;
    Thromb Haemost; 2003 Oct; 90(4):642-53. PubMed ID: 14515185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB.
    Joyce DE; Grinnell BW
    Crit Care Med; 2002 May; 30(5 Suppl):S288-93. PubMed ID: 12004250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introduction: rationale for using drotrecogin alfa (activated) in patients with severe sepsis.
    Dhainaut JF
    Am J Surg; 2002 Dec; 184(6A Suppl):S5-10. PubMed ID: 12521612
    [No Abstract]   [Full Text] [Related]  

  • 8. New thoughts on sepsis: the unifier of critical care.
    Schulman CS; Hare K
    Dimens Crit Care Nurs; 2003; 22(1):20-30. PubMed ID: 12548098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma.
    Dahabreh Z; Dimitriou R; Chalidis B; Giannoudis PV
    Expert Opin Drug Saf; 2006 Jan; 5(1):67-82. PubMed ID: 16370957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated protein C and sepsis.
    O'Brien LA; Gupta A; Grinnell BW
    Front Biosci; 2006 Jan; 11():676-98. PubMed ID: 16146761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of severe sepsis with Xigris: implications for the clinical nurse specialist.
    Powers J; Jacobi J
    Clin Nurse Spec; 2003 May; 17(3):128-30. PubMed ID: 12792186
    [No Abstract]   [Full Text] [Related]  

  • 12. Comment on "Drotrecogin Alfa (activated) (recombinant human protein C, rhAPC) reduces host coagulopathy response in patients with severe sepsis".
    Taylor F
    Thromb Haemost; 2003 Oct; 90(4):560-1. PubMed ID: 14515171
    [No Abstract]   [Full Text] [Related]  

  • 13. Recombinant human activated protein C: current insights into its mechanism of action.
    Levi M; van der Poll T
    Crit Care; 2007; 11 Suppl 5(Suppl 5):S3. PubMed ID: 18269690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human activated protein C.
    Hughes M
    Int J Antimicrob Agents; 2006 Aug; 28(2):90-4. PubMed ID: 16837170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
    Barton P; Kalil AC; Nadel S; Goldstein B; Okhuysen-Cawley R; Brilli RJ; Takano JS; Martin LD; Quint P; Yeh TS; Dalton HJ; Gessouron MR; Brown KE; Betts H; Levin M; Macias WL; Small DS; Wyss VL; Bates BM; Utterback BG; Giroir BP
    Pediatrics; 2004 Jan; 113(1 Pt 1):7-17. PubMed ID: 14702440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.
    De Backer D
    Drug Saf; 2007; 30(11):995-1010. PubMed ID: 17973539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Staging of the pathophysiologic responses of the primate microvasculature to Escherichia coli and endotoxin: examination of the elements of the compensated response and their links to the corresponding uncompensated lethal variants.
    Taylor FB
    Crit Care Med; 2001 Jul; 29(7 Suppl):S78-89. PubMed ID: 11445739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breakthrough found in treatment of severe sepsis.
    Clin Resour Manag; 2001 Jul; 2(7):107-9. PubMed ID: 11482248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drotrecogin alfa: a role in emergency department treatment of severe sepsis?
    McLeay AM
    Emerg Med Australas; 2004 Aug; 16(4):324-35. PubMed ID: 15283720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A new drug which saves lives. Sepsis: chaos in the body--recent aspects of pathophysiology and therapy].
    Haas I
    Krankenpfl J; 2002; 40(10-12):310-4. PubMed ID: 12600015
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.